New Delhi: Drug major Cipla on Wednesday said it has received an establishment inspection report (EIR) from the US health regulator for its Indore plant after completion of inspection there.
The company has "received Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Indore facility indicating formal closure of the USFDA inspection conducted in July/August, 2015", Cipla said in a filing to the BSE.
EIR is given after successful completion of inspection by the US regulator.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
